Amgen Inc. discovers, develops, manufactures, and delivers human therapeutics worldwide. The company's principal products include Enbrel to treat plaque psoriasis, rheumatoid arthritis, and psoriatic arthritis; Otezla for the treatment of adult patients with plaque psoriasis, psoriatic arthritis, and oral ulcers associated with Behçet's disease; Prolia to treat postmenopausal women with osteoporosis; XGEVA for skeletal-related events prevention; Repatha, which reduces the risks of myocardial infarction, stroke, and coronary revascularization; Nplate for the treatment of patients with immune thrombocytopenia; KYPROLIS to treat patients with relapsed or refractory multiple myeloma; Aranesp to treat a lower-than-normal number of red blood cells and anemia; EVENITY for the treatment of osteoporosis in postmenopausal for men and women; Vectibix to treat patients with wild-type RAS metastatic colorectal cancer; BLINCYTO for the treatment of patients with acute lymphoblastic leukemia; TEPEZZA to treat thyroid eye disease; and KRYSTEXXA for the treatment of chronic refractory gout. It also markets other products, including Neulasta, MVASI, AMJEVITA/AMGEVITA, TEZSPIRE, Parsabiv, Aimovig, LUMAKRAS/LUMYKRAS, EPOGEN, KANJINTI, TAVNEOS, RAVICTI, UPLIZNA and PROCYSBI. The company serves healthcare providers, including physicians or their clinics, dialysis centers, hospitals, and pharmacies. It distributes its products through pharmaceutical wholesale distributors, as well as direct-to-consumer channels. The company has collaboration agreements with AstraZeneca plc for the development and commercialization of TEZSPIRE; Novartis Pharma AG to develop and commercialize Aimovig; UCB for the development and commercialization of EVENITY; Kyowa Kirin Co., Ltd. for rocatinlimab development and commercialization; and BeiGene, Ltd. for oncology products expansion and development. Amgen Inc. was incorporated in 1980 and is headquartered in Thousand Oaks, California.
Date |
For |
Estimate |
Reported |
Surprise |
surprise % |
2024-05-02 |
2024-03 |
3.76 |
3.96 |
0.2 |
5.32% |
2024-02-06 |
2023-12 |
4.66 |
4.71 |
0.05 |
1.07% |
2023-10-31 |
2023-09 |
4.65 |
4.96 |
0.31 |
6.67% |
2023-08-03 |
2023-06 |
4.44 |
5 |
0.56 |
12.61% |
2023-04-27 |
2023-03 |
3.84 |
3.98 |
0.14 |
3.65% |
2023-01-31 |
2022-12 |
4.04 |
4.09 |
0.05 |
1.24% |
Date |
Firm |
Action |
From |
To |
2023-10-19 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-10-16 |
Argus Research |
Upgrade |
Buy |
Buy |
2023-10-11 |
Jefferies |
Upgrade |
Buy |
Buy |
2023-10-10 |
Leerink Partners |
Upgrade |
Market Perform |
Outperform |
2023-10-08 |
Oppenheimer |
Upgrade |
Outperform |
Outperform |
2023-09-17 |
Argus Research |
Upgrade |
Buy |
Buy |
Date |
Name |
Relation |
Quantity |
Description |
2024-03-05 |
BRADWAY ROBERT A |
Chief Executive Officer |
683.91K |
Stock Award(Grant) |
2024-03-05 |
BUSCH MATTHEW C. |
Officer |
4.80K |
Stock Award(Grant) |
2024-03-05 |
GORDON MURDO |
Officer |
57.57K |
Stock Award(Grant) |
2024-03-05 |
GRAHAM JONATHAN P |
General Counsel |
39.92K |
Stock Award(Grant) |
2024-03-05 |
GRIFFITH PETER H. |
Chief Financial Officer |
39.25K |
Stock Award(Grant) |
2024-05-02 |
GRYGIEL NANCY A |
Officer |
9.98K |
Sale |
Institution Ownership
...
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Group Inc |
48.87M |
10.85B |
9.14% |
2023-06-29 |
Blackrock Inc. |
46.95M |
10.42B |
8.78% |
2023-06-29 |
State Street Corporation |
29.10M |
6.46B |
5.44% |
2023-06-29 |
Primecap Management Company |
14.74M |
3.27B |
2.75% |
2023-06-29 |
Morgan Stanley |
13.60M |
3.02B |
2.54% |
2023-06-29 |
Geode Capital Management, LLC |
11.80M |
2.62B |
2.21% |
Report Date |
Organization |
Position |
Value |
Percentage |
2023-06-29 |
Vanguard Total Stock Market Index Fund |
16.66M |
3.70B |
3.11% |
2023-06-29 |
Vanguard 500 Index Fund |
12.72M |
2.82B |
2.38% |
2023-08-30 |
Invesco ETF Tr-Invesco QQQ Tr, Series 1 ETF |
9.06M |
2.32B |
1.69% |
2023-06-29 |
Vanguard/Primecap Fund |
8.88M |
1.97B |
1.66% |
2023-05-30 |
Schwab Strategic Tr-Schwab U.S. Dividend Equity ETF |
7.89M |
1.74B |
1.48% |
2023-05-30 |
Fidelity 500 Index Fund |
5.98M |
1.32B |
1.12% |
Dividend |
Date |
2.25 |
2024-05-17 |
2.25 |
2024-05-16 |
2.25 |
2024-02-16 |
2.25 |
2024-02-15 |
2.13 |
2023-11-16 |
2.13 |
2023-08-18 |
Split |
Date |
2 : 1 |
1999-11-22 |
2 : 1 |
1999-03-01 |
2 : 1 |
1995-08-16 |
3 : 1 |
1991-09-11 |
2 : 1 |
1990-08-13 |